Citation Impact 2023
Journal Impact Factor: 9.5
5-year Journal Impact Factor: 9.4
Source Normalized Impact per Paper (SNIP): 1.953
SCImago Journal Rank (SJR): 3.024
Speed 2023
Submission to first editorial decision (median days): 5
Submission to acceptance (median days): 72
Usage 2023
Downloads: 1,041,489
Altmetric mentions: 353
Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma
The advent of BTK inhibitors has changed the treatment of patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The first-in-class BTK inhibitor ibrutinib has shown remarkable therap...